2. Academic Validation
  3. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway

Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway

  • Mol Cancer Ther. 2014 May;13(5):1078-91. doi: 10.1158/1535-7163.MCT-13-0709.
Peiwen Yu 1,  A Douglas Laird,  Xiangnan Du,  Jianming Wu,  Kwang-Ai Won,  Kyoko Yamaguchi,  Pin Pin Hsu,  Fawn Qian,  Christopher T Jaeger,  Wentao Zhang,  Chris A Buhr,  Paula Shen,  Wendy Abulafia,  Jason Chen,  Jenny Young,  Arthur Plonowski,  F Michael Yakes,  Felix Chu,  Michelle Lee,  Frauke Bentzien,  Sanh Tan Lam,  Stephanie Dale,  David J Matthews,  Peter Lamb,  Paul Foster
Affiliations

Affiliation

  • 1 Authors' Affiliation: Exelixis, Inc., South San Francisco, California.
PMID: 24634413 DOI: 10.1158/1535-7163.MCT-13-0709
Abstract

Activation of the PI3K (phosphoinositide 3-kinase) pathway is a frequent occurrence in human tumors and is thought to promote growth, survival, and resistance to diverse therapies. Here, we report pharmacologic characterization of the pyridopyrimidinone derivative XL765 (SAR245409), a potent and highly selective pan inhibitor of class I PI3Ks (α, β, γ, and δ) with activity against mTOR. Broad kinase selectivity profiling of >130 protein kinases revealed that XL765 is highly selective for class I PI3Ks and mTOR over other kinases. In cellular assays, XL765 inhibits the formation of PIP(3) in the membrane, and inhibits phosphorylation of Akt, p70S6K, and S6 phosphorylation in multiple tumor cell lines with different genetic alterations affecting the PI3K pathway. In a panel of tumor cell lines, XL765 inhibits proliferation with a wide range of potencies, with evidence of an impact of genotype on sensitivity. In mouse xenograft models, oral administration of XL765 results in dose-dependent inhibition of phosphorylation of Akt, p70S6K, and S6 with a duration of action of approximately 24 hours. Repeat dose administration of XL765 results in significant tumor growth inhibition in multiple human xenograft models in nude mice that is associated with antiproliferative, antiangiogenic, and proapoptotic effects.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z